Bruce Rogers - Apr 1, 2022 Form 4 Insider Report for Morphic Holding, Inc. (MORF)

Role
Chief Scientific Officer
Signature
/s/ Robert Farrell as attorney-in-fact for Bruce Rogers
Stock symbol
MORF
Transactions as of
Apr 1, 2022
Transactions value $
-$367,080
Form type
4
Date filed
4/1/2022, 09:15 PM
Previous filing
Jan 19, 2022
Next filing
May 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MORF Common Stock Options Exercise $43.2K +10K +9.72% $4.32* 113K Apr 1, 2022 Direct
transaction MORF Common Stock Sale -$302K -7.38K -6.53% $40.89 106K Apr 1, 2022 Direct F1, F2
transaction MORF Common Stock Sale -$109K -2.63K -2.49% $41.42 103K Apr 1, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MORF Stock Option (right to buy Common Stock) Options Exercise $0 -10K -5.96% $0.00 158K Apr 1, 2022 Common Stock 10K $4.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.29 to $41.27 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.30 to $41.72 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option vests as to 2.0833% of the total shares monthly, beginning January 14, 2019, with 100% of the total shares vested and exercisable on December 14, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.